Financial Performance - The company's operating revenue for Q1 2022 was CNY 367,925,505.63, representing a 34.58% increase compared to CNY 273,392,371.83 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was CNY 161,777,968.14, up 33.44% from CNY 121,239,486.28 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 148,627,173.03, reflecting a 25.53% increase from CNY 118,400,289.91 in the previous year[4] - The basic earnings per share for Q1 2022 was CNY 0.37, which is a 54.17% increase from CNY 0.24 in the previous year[4] - Total operating revenue for the current period reached ¥367,925,505.63, a significant increase of 34.7% compared to ¥273,392,371.83 in the previous period[28] - Operating profit for the current period was ¥167,770,281.15, up 35.8% from ¥123,477,888.03 in the previous period[31] - Net profit attributable to the parent company was ¥161,777,968.14, representing a 33.5% increase from ¥121,239,486.28 in the previous period[34] - Basic and diluted earnings per share increased to ¥0.37 from ¥0.24, reflecting a growth of 54.2%[34] Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 22,275,788.10, a significant increase of 97.14% compared to CNY 11,299,484.87 in the same period last year[4] - The net cash flow from operating activities was $22,275,788.10, an increase from $11,299,484.87 in the previous period, reflecting a growth of approximately 97.5%[38] - Total cash outflow from operating activities amounted to $335,379,669.36, compared to $259,947,570.35 previously, indicating a rise of about 29%[38] - The net cash flow from investing activities was -$215,463,507.52, an improvement from -$269,422,298.57, showing a reduction in losses by approximately 20%[38] - Cash inflow from financing activities totaled $448,281,111.11, down from $890,330,850.00, representing a decrease of about 49.6%[38] - The net cash flow from financing activities was $224,921,521.49, compared to $759,214,164.72 previously, indicating a decline of approximately 70.4%[38] - The ending balance of cash and cash equivalents was $470,600,079.22, a decrease from $856,254,087.18, reflecting a drop of about 45%[38] - The company reported a cash increase of $31,733,802.07 during the period, compared to an increase of $500,767,809.78 in the previous period[38] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 4,939,389,761.87, marking a 5.94% increase from CNY 4,662,239,616.98 at the end of the previous year[4] - The total liabilities of the company as of March 31, 2022, were CNY 2,229,657,524.37, up from CNY 2,120,484,168.47, marking an increase of about 5.1%[24] - The company's equity attributable to shareholders at the end of Q1 2022 was CNY 2,709,732,237.50, up 6.61% from CNY 2,541,755,448.51 at the end of the previous year[4] - The company's equity attributable to shareholders rose to CNY 2,709,732,237.50 from CNY 2,541,755,448.51, reflecting an increase of approximately 6.6%[27] - The non-current assets totaled CNY 2,978,498,774.80, up from CNY 2,637,208,856.20, indicating a growth of about 12.9%[21] - Short-term borrowings increased by 34.27% to CNY 466,069,697.24 from CNY 347,114,881.92 in the previous year[8] - Short-term borrowings increased to CNY 466,069,697.24 from CNY 347,114,881.92, representing a rise of approximately 34.3%[21] - The company's contract liabilities increased to CNY 46,588,790.55 from CNY 40,639,330.34, showing a growth of about 14.3%[24] - The total current liabilities were CNY 1,039,435,709.09, slightly down from CNY 1,039,683,193.63, indicating a marginal decrease of about 0.02%[24] Expenses - Research and development expenses increased to ¥56,659,055.19, a rise of 12.9% compared to ¥50,208,146.21 in the previous period[31] - Sales expenses rose to ¥47,706,957.68, an increase of 22.6% from ¥38,904,005.07 in the previous period[31] - Total operating costs for the current period were ¥212,061,775.12, up 38.3% from ¥153,207,132.77 in the previous period[28] - Income tax expenses increased to ¥6,010,278.61 from ¥2,253,300.85, reflecting a rise of 166.5%[31] Other Income and Subsidies - Government subsidies recognized in Q1 2022 amounted to CNY 13,015,588.30, contributing to the increase in other income by 295.29% compared to CNY 3,292,648.97 in the previous year[8] - The company reported other income of ¥13,015,588.30, significantly higher than ¥3,292,648.97 in the previous period[31] Financial Reporting - The report for the first quarter was not audited, which may impact the reliability of the financial data presented[39]

Financial Performance - The company's revenue for Q3 2021 reached ¥513,587,330.59, representing a 35.03% increase compared to the same period last year[4] - Net profit attributable to shareholders for the same period was ¥165,041,086.70, up 30.50% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥165,101,415.02, reflecting a significant increase of 51.76% compared to the previous year[4] - The company reported a 36.93% increase in net profit attributable to shareholders for the year-to-date period, totaling ¥390,176,301.10[4] - Net profit for the period was CNY 390,176,301.10, representing a 37% increase compared to CNY 284,946,031.60 in the previous year[39] - The total comprehensive income for the period reached ¥390,176,301.10, compared to ¥284,946,031.60 in the previous period, representing an increase of approximately 37%[43] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,455,245,679.97, marking a 45.79% increase from the end of the previous year[4] - Total assets reached CNY 4,455,245,679.97, an increase of 45.7% compared to CNY 3,055,999,316.62 last year[34] - The company's total liabilities increased by 85.92% to ¥315,651,181.00 due to short-term borrowing for working capital[9] - Total liabilities amounted to CNY 1,846,700,406.76, a significant increase from CNY 1,016,848,007.93 year-on-year[35] - Short-term borrowings increased to CNY 315,651,181.00, compared to CNY 169,773,525.00 in the same period last year[34] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥156,679,118.33, showing a 43.47% increase compared to the same period last year[4] - Cash inflow from operating activities totaled ¥1,417,676,860.54, up from ¥1,154,502,270.42, indicating a rise of about 22.8%[44] - Net cash flow from operating activities was ¥156,679,118.33, compared to ¥109,210,599.47, showing an increase of about 43.3%[47] - Cash inflow from financing activities amounted to ¥1,372,325,849.73, up from ¥920,352,893.97, representing an increase of approximately 49.2%[50] - The net cash flow from financing activities was ¥905,996,049.53, compared to ¥623,221,736.79, indicating a growth of about 45.3%[50] - The ending balance of cash and cash equivalents was ¥623,880,152.83, compared to ¥428,367,728.56 in the previous period, reflecting an increase of approximately 45.5%[50] Shareholder Information - The company's basic earnings per share for Q3 2021 was ¥0.37, an increase of 27.85% year-on-year[4] - Basic and diluted earnings per share both increased to ¥0.89 from ¥0.65, reflecting a growth of 36.9%[43] - As of September 30, 2021, the company had 1.13 million shares of restricted stock remaining after the first unlock period, which represents 0.1271% of the total share capital[25] Inventory and Expenses - Inventory levels rose significantly by 198.71% to ¥281,054,779.46, indicating increased production and R&D material requirements[9] - Research and development expenses increased to CNY 204,105,266.69, a rise of 23.3% from CNY 165,400,436.31 year-on-year[39] - Cash outflow for purchasing goods and services was ¥720,757,934.03, compared to ¥523,780,105.91 in the previous period, marking an increase of approximately 37.6%[47] Other Financial Metrics - The weighted average return on equity decreased by 6.92% to 7.22% in the current reporting period[4] - The company's fixed assets increased to RMB 701.34 million, up from RMB 536.60 million, reflecting a growth of 30.6%[29] - Non-current assets totaled CNY 2,583,421,577.53, up 42% from CNY 1,823,214,597.62 in the previous year[34] - The company issued 8.5 million convertible bonds in February 2021, with a conversion price adjusted to RMB 46.03 per share effective from July 9, 2021[22] - The company plans to implement a second employee stock ownership plan, which has been approved and is currently in progress[23] - The company reported a significant increase in prepayments, which rose to RMB 61.04 million from RMB 37.06 million, marking a growth of 64.8%[29] - The company’s investment properties decreased slightly to RMB 24.64 million from RMB 26.21 million, indicating a decline of 6%[29] Audit Information - The company did not undergo an audit for the third quarter report[51]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 623,056,090.07, representing a 55.11% increase compared to CNY 401,680,875.78 in the same period last year[27]. - The net profit attributable to shareholders for the first half of 2021 was CNY 225,135,214.40, up 42.06% from CNY 158,477,357.61 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 219,494,393.01, reflecting a 39.27% increase from CNY 157,608,676.25 year-on-year[27]. - The net cash flow from operating activities was CNY 62,368,223.31, which is a 21.36% increase compared to CNY 51,389,123.19 in the same period last year[27]. - Basic earnings per share for the first half of 2021 were CNY 0.52, an increase of 44.44% from CNY 0.36 in the previous year[27]. - Diluted earnings per share were CNY 0.50, up 38.89% from CNY 0.36 year-on-year[27]. - Total assets at the end of the reporting period were CNY 4,154,893,453.26, a 35.96% increase from CNY 3,055,999,316.62 at the end of the previous year[27]. - Net assets attributable to shareholders at the end of the reporting period were CNY 2,423,787,409.00, an 18.86% increase from CNY 2,039,151,308.69 at the end of the previous year[27]. Research and Development - The company has a strong R&D team with over 430 personnel, accounting for nearly one-third of the total workforce of over 1,100 employees[49]. - The company holds over 59 patents, including 56 invention patents, and has 136 product approval numbers, with 55 for domestic chemical drugs and 55 for overseas formulations[38]. - The company plans to continue focusing on high-end generic drugs and aims to enhance its product pipeline in innovative drugs targeting major diseases[42]. - Research and development expenses increased by 59.28% to ¥121,728,697.56 from ¥76,423,294.44, indicating a strong commitment to innovation[91]. - The company has a robust pipeline of research projects that are expected to drive future growth and long-term development[86]. Market Presence and Sales - The company has established a marketing network covering over 15,000 medical institutions across all provinces, cities, and autonomous regions in China, including over 4,000 secondary and higher-level hospitals[87]. - The company has signed exclusive sales contracts with multiple distributors in Europe and the United States, expanding its international market presence[87]. - The company is focused on expanding its market presence through strategic product offerings and compliance with national essential drug lists[56]. - The company is actively expanding its market presence through global registration strategies and product diversification[76]. - The company focuses on market expansion through collaboration with distributors and direct sales to retail pharmacies[68]. Production and Quality Management - The company has established high-end manufacturing bases in Haikou, Hangzhou, and Anqing, covering various dosage forms including injections, tablets, and capsules[39]. - The company has established a complete GMP management system in compliance with requirements from the FDA, EMA, WHO, and NMPA, ensuring standardized production processes[63]. - Quality inspections are mandatory for all incoming materials, ensuring compliance with national and internal standards before storage[61]. - Each batch of products must pass strict quality inspections before being released for sale, ensuring compliance with quality standards[65]. - The company implements a dual-lock management system for special and hazardous materials, enhancing safety in material storage[62]. Financial Management and Investments - The total amount of raised funds was ¥169,216.66 million, with ¥16,119.26 million invested during the reporting period[101]. - The company has pledged assets including real estate and land use rights valued at ¥29,279,549.92 as collateral for loans[98]. - The total committed investment amount for the annual production line project is CNY 21,435.29 million, with a cumulative investment of CNY 21,500.43 million, achieving an investment progress of 100.30%[106]. - The company plans to temporarily use up to CNY 200 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[112]. - The company has confirmed that all related transactions are conducted at market prices, maintaining transparency and fairness in dealings[161]. Risks and Challenges - The company acknowledges potential risks in production and operations, including industry policies and drug development challenges[7]. - The pharmaceutical industry is heavily influenced by national policies, with ongoing pressures from medical insurance cost control and bidding price reductions impacting drug sales[121]. - The company faces risks related to international trade protectionism and globalization challenges, which may affect drug registration and export[121]. - The lengthy and complex R&D process for pharmaceutical products poses significant risks, including market changes post-approval[121]. - Sales of prescription drugs depend heavily on physician awareness and market demand, with potential risks from market competition and promotional activities[121]. Corporate Governance and Social Responsibility - The company has committed to transparency in its operations, ensuring that any potential conflicts of interest are managed appropriately[142]. - The company actively engages in social responsibility, including a donation of over 5 million yuan worth of medicines to aid flood relief efforts in Zhengzhou[135]. - The company has not faced any environmental penalties and adheres to strict environmental protection regulations during its operations[134]. - The company has made commitments to avoid unfair benefit transfers and to ensure that executive compensation is linked to the execution of return compensation measures[142]. - The company has reported no overdue commitments as of the end of the reporting period, indicating strong compliance with its obligations[139].

Financial Performance - The company's operating revenue for 2020 was ¥1,188,603,424.51, representing a 25.10% increase from ¥950,095,207.86 in 2019 [22]. - The net profit attributable to shareholders for 2020 was ¥407,450,895.97, a 35.30% increase from ¥301,147,028.57 in 2019 [22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥380,235,764.93, up 34.14% from ¥283,461,483.69 in 2019 [22]. - The net cash flow from operating activities for 2020 was ¥332,075,817.29, a significant increase of 54.19% compared to ¥215,374,300.86 in 2019 [22]. - The total assets at the end of 2020 reached ¥3,055,999,316.62, marking a 77.64% increase from ¥1,720,306,871.36 at the end of 2019 [22]. - The net assets attributable to shareholders at the end of 2020 were ¥2,039,151,308.69, up 77.95% from ¥1,145,941,429.17 at the end of 2019 [22]. - The company reported a basic and diluted earnings per share of ¥0.94 for 2020, a 32.39% increase from ¥0.71 in 2019 [22]. - In 2020, the company achieved operating revenue of CNY 1,188.60 million, a year-on-year increase of 25.10% [77]. - The net profit attributable to shareholders reached CNY 407.45 million, up 35.30% year-on-year [77]. - Total assets increased to CNY 3,055.99 million, a growth of 77.64% compared to the previous year [77]. Dividend Distribution - The company plans to distribute a cash dividend of 1.87 RMB per 10 shares to all shareholders, based on a total of 437,029,279 shares [6]. - The total cash dividend distributed was RMB 81,724,475.17, representing 20.06% of the net profit attributable to shareholders [166]. - The company reported a distributable profit of RMB 842,731,626.18 for the year 2020 [163]. - Over the past three years, the cash dividend distribution has been consistent, with 2018 at RMB 38,467,050.30, 2019 at RMB 60,448,142.91, and 2020 at RMB 81,724,475.17 [166]. - The company has maintained a cash dividend payout ratio of approximately 20% over the last three years [166]. - The company has not proposed any capital reserve conversion or stock bonuses for the reporting period [163]. - The company has complied with its profit distribution plan as per its articles of association [162]. - The company’s profit distribution plan aligns with the legal requirements and internal regulations [162]. Research and Development - The company has a total of over 70 ongoing research projects, including generic drugs and improved new drugs [35]. - The company has a strong emphasis on R&D, with a dedicated expert committee guiding major technology projects and evaluations [69]. - R&D personnel increased by 24.81% year-on-year, significantly higher than the overall employee growth rate [82]. - Total R&D investment reached ¥283,151,872.64, representing 23.82% of operating revenue, an increase from 21.51% in 2019 [114]. - The company is focusing on developing generic drugs, with 25 projects classified as NP (New Product) and 12 as ANDA (Abbreviated New Drug Application) [89]. - The company is committed to increasing R&D investment, focusing on high-difficulty generic drugs with good future competitive landscapes, ensuring the launch of high-value products [152]. - The company is actively pursuing consistency evaluations for its products, as those that fail to meet standards may adversely affect future operations [156]. Market Expansion and Sales - The company has established a marketing network covering over 15,000 medical institutions across all provinces, cities, and autonomous regions in China, including more than 3,700 secondary and higher-level hospitals [69]. - The company has signed exclusive sales contracts with multiple distributors in Europe and the United States, expanding its international market presence [69]. - The company is actively pursuing market expansion with multiple projects in the pipeline, including 8 projects in the United States and 6 in the European Union [89]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain [175]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential M&A activities [175]. - The company plans to deepen its product chain in areas such as anti-allergy, anti-tumor, and cardiovascular medications while exploring international innovative drugs [86]. Production and Quality Control - The company has established a comprehensive GMP management system in compliance with standards set by the FDA, EMA, WHO, and NMPA, ensuring standardized production processes [50]. - The company has implemented strict quality control measures throughout the production process, ensuring compliance with high-quality standards [61]. - Quality inspections are mandatory for all incoming materials, ensuring compliance with national and internal standards before storage [46]. - The company has established a procurement model based on "production-driven purchasing," ensuring raw materials are acquired according to production plans and inventory levels [43]. - A strict supplier management system is in place, requiring suppliers to meet specific production qualifications and undergo regular evaluations [44]. Strategic Focus and Future Plans - The company’s strategic focus is on differentiation, integration of raw materials and formulations, and internationalization in high-end manufacturing [76]. - The long-term strategy includes dual submissions for innovative drugs in both the U.S. and China, targeting multiple therapeutic areas [152]. - The company is focusing on transitioning from international generic drugs to international innovative drugs, with a short-term strategy emphasizing high-end generic drug manufacturing and compliance in global production capabilities [150]. - The company is committed to expanding its international market presence despite the complexities of the current global situation [86]. Compliance and Governance - The company has maintained a continuous relationship with Tianjian Accounting Firm for 8 years, with an audit fee of 900,000 RMB [191]. - The company’s management has committed to ensuring that any misleading statements in the prospectus will lead to compensation for investors [184]. - The company has not faced any bankruptcy reorganization matters during the reporting period [192]. - The company reported no non-operating fund occupation by controlling shareholders during the reporting period [187]. Legal and Contractual Matters - The arbitration case with Zhongtian Construction involves a dispute over the construction cost of the injection production building, with an amount in dispute of 23.06 million yuan [193]. - The contract dispute with Nanjing Kavin Dishi has an amount in dispute of 3.66 million yuan, with no significant adverse impact on the company's main products or core patents [193].

Financial Performance - The company's operating revenue for 2020 was ¥1,188,603,424.51, representing a 25.10% increase from ¥950,095,207.86 in 2019[22]. - The net profit attributable to shareholders for 2020 was ¥407,450,895.97, a 35.30% increase compared to ¥301,147,028.57 in 2019[22]. - The net profit after deducting non-recurring gains and losses was ¥380,235,764.93, up 34.14% from ¥283,461,483.69 in 2019[22]. - The net cash flow from operating activities reached ¥332,075,817.29, marking a 54.19% increase from ¥215,374,300.86 in 2019[22]. - The total assets at the end of 2020 were ¥3,055,999,316.62, a 77.64% increase from ¥1,720,306,871.36 at the end of 2019[22]. - The net assets attributable to shareholders increased to ¥2,039,151,308.69, up 77.95% from ¥1,145,941,429.17 at the end of 2019[22]. - In 2020, the company achieved operating revenue of CNY 1,188.60 million, a year-on-year increase of 25.10%[77]. - The net profit attributable to shareholders reached CNY 407.45 million, up 35.30% year-on-year[77]. - Total assets increased by 77.64% to CNY 3,055.99 million, while net assets rose by 77.95% to CNY 2,039.15 million[77]. Dividend Distribution - The company plans to distribute a cash dividend of 1.87 RMB per 10 shares to all shareholders, based on a total of 437,029,279 shares[6]. - The cash dividend for the year is set at 1.87 yuan per 10 shares, totaling 81,724,475.17 yuan (including tax)[160]. - The total cash dividend distributed was RMB 81,724,475.17, representing 20.06% of the net profit attributable to shareholders[166]. - The company reported a distributable profit of RMB 842,731,626.18 for the year 2020[163]. - Over the past three years, the cash dividend distribution has been consistent, with 20.07% in 2019 and 21.20% in 2018[166]. - The company has not proposed any cash dividend distribution plan for the current reporting period despite having positive distributable profits[166]. - The cash dividend for 2019 was RMB 60,448,142.91, also representing 20.07% of the net profit attributable to shareholders[166]. - The cash dividend for 2018 was RMB 38,467,050.30, which accounted for 21.20% of the net profit attributable to shareholders[166]. Research and Development - The company has 70+ ongoing projects, including generic drugs and new drug formulations[35]. - The company’s R&D strategy focuses on new product development, with a complete R&D process from project selection to registration management[69]. - In 2020, the company increased R&D personnel by 24.81%, significantly higher than the overall employee growth rate[82]. - R&D investment amounted to ¥283,151,872.64, representing 23.82% of operating revenue, an increase from 21.51% in 2019[114]. - The company is focusing on transitioning from international generic drugs to international innovative drugs, with a strong foundation built over more than a decade in the generic drug sector[150]. - The company is committed to increasing R&D investment, focusing on high-difficulty generic drugs with good future competitive landscapes[152]. - The company has a robust pipeline of ongoing R&D projects, which are expected to provide potential growth points domestically and internationally[69]. - The company has 38 projects currently under review for registration, primarily in the fields of cardiovascular, infectious, and digestive system diseases[89]. Market Expansion and Sales - The marketing network covers thousands of hospitals and medical institutions across China, with over a thousand distributors and delivery partners[35]. - The company has established a marketing network covering over 15,000 medical institutions across all provinces, cities, and autonomous regions in China, including more than 3,700 secondary and higher-level hospitals[69]. - The company has signed exclusive sales contracts with multiple distributors in Europe and the United States, expanding its international market presence[69]. - The company is actively pursuing market expansion with multiple projects under review in countries including China, the United States, Canada, and the European Union[89][91]. - The company plans to enhance its supply chain efficiency, aiming to reduce costs by 8% over the next year[175]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential M&A activities[175]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing drug efficacy and reducing side effects[175]. Compliance and Risk Management - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[6]. - The company has faced potential risks in its operations, including industry policies, price reductions in bidding, and unmet expectations in drug development[6]. - The company faces risks including R&D failures, loss of core technical personnel, and challenges in adapting to changes in the healthcare system[153]. - The company is actively promoting consistency evaluations for its products, as failure to comply could adversely affect future operations[156]. - The company emphasizes the importance of maintaining product quality, as any issues could impact its market reputation and operational stability[153]. Corporate Governance - The company operates under the supervision of a certified accounting firm, Tianjian Accounting Firm, ensuring the accuracy and completeness of financial reports[21]. - The company has maintained a continuous relationship with Tianjian Accounting Firm for 8 years, with an audit fee of 900,000 RMB[191]. - The company’s management has committed to compensating investors for losses due to any misleading statements in the prospectus[182]. - The company’s board and senior management pledged to restrict personal consumption behaviors and not misuse company assets for unrelated investments[180]. - The company has not faced any bankruptcy reorganization matters during the reporting period[192]. Production and Quality Control - The company has established a comprehensive GMP management system in compliance with standards set by the FDA, EMA, WHO, and NMPA, ensuring standardized production processes[50]. - The company implements strict quality control measures throughout the drug development and production process, ensuring compliance with high-quality standards[61]. - Quality inspections are mandatory for all incoming materials, ensuring compliance with national and internal standards before acceptance into inventory[46]. - The company has obtained multiple GMP/cGMP certifications for its products, demonstrating its commitment to maintaining high-quality manufacturing practices[62]. Investment and Asset Management - The company has increased its investment in construction projects for factories in Hainan, Zhejiang, and Anhui, contributing to the growth of its fixed assets[57]. - The total investment amount for the reporting period was ¥688,216,686.75, representing a 154.12% increase compared to ¥270,822,055.22 in the previous year[127]. - The company has ongoing major non-equity investments, including a project for producing 1.5 billion dosage forms, with an investment of ¥2,344,846.75 and a cumulative investment of ¥404,283,000[127]. - The company has raised a total of ¥85,430.53 million through public offerings, with ¥47,143.12 million utilized in the current period[133]. - The company has ongoing projects for the construction of various production lines, with total investments amounting to ¥688,216,686.75 and cumulative actual investments of ¥1,503,874,685.28[130].

Financial Performance - The company's revenue for Q1 2021 was ¥273,392,371.83, representing a 60.03% increase compared to ¥170,838,521.57 in the same period last year[10] - Net profit attributable to shareholders was ¥121,239,486.28, up 51.40% from ¥80,080,883.58 year-on-year[10] - Basic earnings per share rose to ¥0.24, a 33.33% increase from ¥0.18 in the same period last year[10] - The company achieved total operating revenue of CNY 273,392,371.83 in Q1 2021, representing a year-on-year growth of 60.03%[23] - The net profit attributable to shareholders increased by 51.40% year-on-year, reaching CNY 121,239,486.28[23] - The total comprehensive income for the period was CNY 121,239,486.28, compared to CNY 80,080,883.58 in the previous period, representing an increase of approximately 51.5%[70] Cash Flow and Liquidity - The net cash flow from operating activities increased by 76.17%, reaching ¥11,299,484.87 compared to ¥6,413,837.93 in the previous year[10] - Cash and cash equivalents rose by 140.41% to CNY 857,425,098.72, primarily due to the proceeds from convertible bond issuance[22] - The company’s cash received from sales increased by 40.66% to CNY 257,236,019.60, indicating improved cash flow from operations[22] - The total cash inflow from operating activities was CNY 271,247,055.22, up from CNY 196,652,351.12, which is an increase of approximately 37.9%[82] - The total cash and cash equivalents at the end of the period reached 856,254,087.18 CNY, up from 108,358,597.61 CNY in the previous period, showing improved liquidity[84] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,987,868,404.28, reflecting a 30.49% increase from ¥3,055,999,316.62 at the end of the previous year[10] - The company reported a total cash inflow from operating activities of CNY 271,247,055.22, up from CNY 196,652,351.12, which is an increase of approximately 37.9%[82] - Current assets totaled approximately CNY 1.71 billion, a significant increase from CNY 1.23 billion as of December 31, 2020, representing a growth of about 38.5%[45] - Total liabilities increased to CNY 1.58 billion from CNY 1.02 billion, reflecting a growth of approximately 55%[51] - The company's equity attributable to shareholders rose to CNY 2.41 billion from CNY 2.04 billion, an increase of about 18.2%[54] Research and Development - Research and development expenses increased by 107.40% to CNY 50,208,146.21, reflecting the company's commitment to enhancing its R&D capabilities[22] - Research and development expenses for the quarter were ¥50,208,146.21, compared to ¥24,208,482.51 in the previous year, showing an increase of approximately 107.5%[64] - Research and development expenses increased to CNY 27,508,965.83 from CNY 14,509,310.61, marking an increase of approximately 89.6%[71] Market and Growth Strategy - The company signed significant orders and continued to expand its domestic and international market presence[23] - The company plans to continue strengthening its competitive position in niche markets while expanding its product sales domestically and internationally[23] - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum in the upcoming quarters[63] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,397[13] - The largest shareholder, Fan Minhua, holds 33.88% of the shares, totaling 148,083,509 shares[13] Government Support and Compliance - The company received government subsidies totaling ¥3,292,648.97 during the reporting period[10] - The company has no significant changes in project feasibility and no issues with the use of raised funds[35] - The company has no violations regarding external guarantees during the reporting period[39] - The company has no non-operating occupation of funds by controlling shareholders and their affiliates during the reporting period[40]

Financial Performance - Operating revenue for the reporting period was CNY 380,361,561.30, up 48.19% year-on-year[10] - Net profit attributable to shareholders was CNY 126,468,673.99, an increase of 47.15% compared to the same period last year[10] - Basic earnings per share decreased by 6.65% to CNY 0.2894[10] - The weighted average return on net assets was 14.14%, an increase of 5.91% compared to the same period last year[10] - Total operating revenue for the current period reached ¥380,361,561.30, a significant increase from ¥256,663,287.11 in the previous period, representing a growth of approximately 48.2%[72] - Net profit for the current period was ¥126,468,673.99, compared to ¥85,945,705.09 in the previous period, reflecting an increase of approximately 47.1%[78] - The company reported a total profit of ¥128,829,779.04, up from ¥88,747,848.97, indicating an increase of approximately 45%[78] - Total comprehensive income for the current period was ¥284,946,031.60, compared to ¥206,030,166.90 in the previous period, showing an increase of approximately 38.2%[96] Assets and Liabilities - Total assets increased by 61.76% to CNY 2,782,796,362.68 compared to the end of the previous year[10] - Net assets attributable to shareholders increased by 70.80% to CNY 1,957,230,609.07 compared to the end of the previous year[10] - Accounts receivable increased by 48.82% to ¥492,581,129.86 due to revenue growth[26] - Inventory rose by 90.43% to ¥132,760,389.44 as production materials increased[26] - Total assets under construction reached ¥900,677,634.02, a 73.05% increase, attributed to ongoing projects in Hainan, Hangzhou, and Anhui[26] - Current liabilities increased to ¥596,622,942.45 from ¥432,850,178.27, representing a rise of about 37.8%[62] - Total liabilities reached ¥825,565,753.61, up from ¥574,365,442.19, indicating an increase of approximately 43.7%[62] - Shareholders' equity rose to ¥1,957,230,609.07 from ¥1,145,941,429.17, reflecting a growth of about 71.1%[65] Cash Flow - Net cash flow from operating activities increased by 64.40% to CNY 57,821,476.28[10] - Cash received from sales grew by 57.14% to ¥929,064,197.43, driven by increased sales volume[26] - Cash flow from operating activities generated ¥109,210,599.47, compared to ¥74,026,431.15 in the previous period, reflecting an increase of about 47.5%[106] - Cash flow from investing activities showed a net outflow of ¥499,969,800.35, worsening from a net outflow of ¥274,387,542.40 in the previous period[109] - Cash flow from financing activities resulted in a net inflow of ¥623,221,736.79, compared to a net inflow of ¥87,223,211.91 in the previous period, indicating a significant increase[109] Research and Development - Research and development expenses increased by 46.40% to ¥165,400,436.31, reflecting higher investment in R&D[26] - Research and development expenses surged to ¥88,977,141.87, compared to ¥40,575,415.23, marking an increase of about 119.5%[75] - Research and development expenses for the current period amounted to ¥165,400,436.31, compared to ¥112,977,475.88 in the previous period, marking an increase of about 46.5%[89] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,623[14] - The largest shareholder, Fan Minhua, holds 33.89% of the shares, totaling 148,083,509 shares[14] - The company reported a commitment to not seek undue benefits from shareholders or actual controllers, ensuring the protection of the legitimate rights and interests of all shareholders[42] Corporate Governance - The company is committed to adhering to regulatory requirements and maintaining good corporate governance practices[42] - The company has a long-term commitment to maintain operational integrity and transparency in its financial reporting[42] - There were no violations of external guarantees during the reporting period, indicating a stable financial position[50] - The company confirmed that there were no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[51] Market Expansion and Future Guidance - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2021[39] - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between 1.65 billion RMB and 1.75 billion RMB[39] - New product launches are expected to contribute an additional 200 million RMB in revenue over the next two quarters[39]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 401,680,875.78, representing a 14.16% increase compared to CNY 351,870,637.90 in the same period last year[25]. - Net profit attributable to shareholders for the first half of 2020 was CNY 158,477,357.61, a 31.97% increase from CNY 120,084,461.81 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 157,608,676.25, which is a 35.76% increase compared to CNY 116,093,670.65 in the same period last year[25]. - The net cash flow from operating activities was CNY 51,389,123.19, up 32.26% from CNY 38,854,637.71 in the previous year[25]. - Basic earnings per share for the first half of 2020 were CNY 0.57, a 29.55% increase from CNY 0.44 in the same period last year[25]. - Total assets at the end of the reporting period were CNY 2,650,613,917.57, reflecting a 54.08% increase from CNY 1,720,306,871.36 at the end of the previous year[25]. - Net assets attributable to shareholders at the end of the reporting period were CNY 1,783,923,003.70, a 55.67% increase from CNY 1,145,941,429.17 at the end of the previous year[25]. - The company achieved a total operating revenue of 401.68 million yuan, an increase of 14.16% year-on-year[45]. - The net profit attributable to shareholders increased by 31.97% compared to the same period last year[45]. - The company's operating income reached approximately ¥208.29 million, with a net profit of approximately ¥41.79 million, representing a significant contribution to the overall net profit[112]. Assets and Investments - The company's fixed assets at the end of the reporting period amounted to 444.6991 million yuan, an increase of 67.8224 million yuan compared to the beginning of the period, representing an 18% year-on-year growth, primarily due to the construction of fundraising projects and other renovation projects[48]. - The company's intangible assets at the end of the reporting period totaled 96.9090 million yuan, an increase of 13.2429 million yuan compared to the beginning of the period, reflecting a year-on-year increase of 15.83%, mainly due to the purchase of related software[51]. - The balance of construction in progress at the end of the reporting period was 847.2119 million yuan, an increase of 326.7374 million yuan compared to the beginning of the period, which is a 62.78% year-on-year increase, primarily due to investments in fundraising projects and other renovation projects[51]. - The total investment during the reporting period was ¥368,715,193.45, a significant increase of 182.48% compared to ¥130,526,655.45 in the same period last year[94]. - The company has invested RMB 13,000 million in bank financial products using idle raised funds, with no overdue amounts[107]. Research and Development - The company is actively involved in the research and development of new drugs, with a focus on controlled-release formulations and technologies for difficult-to-soluble drugs[35]. - The company has increased R&D investment, securing a patent for a new drug formulation, enhancing its competitive edge[68]. - The company is committed to increasing its investment in scientific research and development, particularly in areas such as anti-allergy, anti-tumor, cardiovascular, pediatric, and geriatric medications[73]. - The company has a robust pipeline of products under development, leveraging its technical advantages in taste masking, sustained release, and solubility to innovate and optimize existing formulations[72]. - The company has a structured approach to managing risks associated with research and development in the pharmaceutical sector[118]. Market and Sales - The company has established a marketing network covering over 15,000 medical institutions across China, including more than 3,600 secondary and higher-level hospitals, facilitating effective distribution and sales[55]. - The company has signed exclusive sales contracts with distributors in Europe and the United States, marking a significant step in its international expansion strategy[55]. - The company is focused on new product development as a strategic core, with a robust pipeline of projects that are expected to drive future growth domestically and internationally[55]. - The company has successfully registered multiple products internationally, including desloratadine tablets in Germany and injectable acyclovir in Cyprus, enhancing its global market presence[47]. - The company actively participated in the national "4+7" volume-based procurement, enhancing market access and sales growth[68]. Risks and Challenges - The company has faced risks related to industry policies, price reductions in bidding, and unmet expectations in drug research and development[8]. - The company is closely monitoring policy changes in the pharmaceutical industry, which may impact drug sales due to price control and procurement policies[118]. - The company faces risks related to international trade protectionism, which may affect drug registration and exports[118]. - The company emphasizes the importance of drug quality, as any quality issues could adversely affect its operations and market reputation[118]. Corporate Governance and Compliance - The company has not classified any non-recurring profit items as recurring profit during the reporting period[31]. - The company has committed to a 36-month lock-up period for shares post-IPO, during which no shares will be transferred or managed by others[132]. - The company has outlined specific measures to ensure compliance with its commitments regarding share transfers and competition[147]. - The company will monitor and address any potential conflicts of interest arising from related party transactions[149]. - The company has made commitments regarding the compensation for any false statements in the prospectus, ensuring accountability[161]. Legal Matters - The company reported a significant ongoing litigation with a claim amounting to 5 million yuan related to a contract dispute[171]. - Another ongoing litigation involves a claim of 365.77 million yuan concerning a cooperation agreement with Nanjing Kavin Dishi Biotechnology Co., Ltd.[171]. - There were no major lawsuits or arbitration matters reported during the period[171]. - The half-year financial report has not been audited[169].

Financial Performance - Total revenue for Q1 2020 was CNY 170,838,521.57, an increase of 8.84% compared to CNY 156,959,330.16 in the same period last year[9] - Net profit attributable to shareholders was CNY 80,080,883.58, representing a growth of 14.38% from CNY 70,014,897.74 year-on-year[9] - Net profit excluding non-recurring gains and losses reached CNY 82,095,991.47, up 17.99% from CNY 69,579,855.27 in the previous year[9] - Basic earnings per share (EPS) was CNY 0.2915, a rise of 14.40% from CNY 0.2548 in the same quarter last year[9] - The company reported a total non-current asset of 1,281,116,342.91 CNY as of March 31, 2020, compared to 1,042,316,620.21 CNY at the end of 2019[46] - The company reported a total profit for the current period of ¥82,087,334.90, an increase from ¥73,036,112.42 in the previous period[67] Cash Flow and Liquidity - Operating cash flow for the period was CNY 6,413,837.93, reflecting a significant increase of 34.28% compared to CNY 4,776,420.42 last year[9] - Cash inflow from operating activities was ¥196,652,351.12, up from ¥140,572,226.43 in the previous period, representing an increase of approximately 39.9%[78] - Cash outflow for purchasing goods and services was ¥109,934,733.02, compared to ¥64,715,101.75 in the previous period, reflecting a significant increase of about 70%[81] - The ending balance of cash and cash equivalents was ¥108,358,597.61, up from ¥62,941,378.53 in the previous period[84] - Cash and cash equivalents decreased by 44.73% to CNY 109.97 million due to significant capital expenditure on construction projects[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,911,516,393.02, an increase of 11.11% from CNY 1,720,306,871.36 at the end of the previous year[9] - The total liabilities increased to ¥296,368,235.74 from ¥292,928,415.15, showing a slight rise of approximately 1.5%[59] - The company's total equity rose to ¥1,271,871,943.01, up from ¥1,192,113,456.74, marking an increase of around 6.7%[59] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,810, with the top ten shareholders holding significant stakes[13] - The largest shareholder, Fan Minhua, holds 35.16% of the shares, totaling 96,597,000 shares[13] Investments and Projects - The company has committed a total of 31,435.29 million CNY for investment projects, with a cumulative investment of 31,612.04 million CNY as of the reporting period, achieving an investment progress of 100.56%[31] - The production line for annual formulation products has reached a completion status of 100.30%, with a total investment of 21,500 million CNY[31] - The construction of the European and American standard injection production line has achieved an investment progress of 101.12%, with a cumulative investment of 10,111.61 million CNY[31] Operational Highlights - The company received several drug approvals, including levofloxacin tablets and injectable bivalirudin, which are now under priority review by the National Medical Products Administration[24] - The company reported a 35.32% increase in cash received from sales of goods and services, totaling CNY 182.88 million, due to sales growth and improved collections[23] - The company plans to continue expanding its domestic and international market presence while increasing investment in technology research and development[24] Changes in Financial Metrics - Cash outflow for purchasing fixed assets and intangible assets rose by 167.36% to CNY 270.96 million, reflecting the transition of ongoing projects to fixed assets[23] - Accounts receivable financing dropped by 69.01% to CNY 6.45 million, attributed to bill endorsement transfers or maturity cashing[23] - Inventory increased by 63.04% to CNY 113.66 million, reflecting higher production material reserves at the beginning of the year[23] - Long-term borrowings surged by 180.96% to CNY 138.93 million, driven by funding needs for ongoing construction projects[23] Compliance and Standards - The company did not undergo an audit for the first quarter report[91] - The company has not applied the new revenue and leasing standards for the current period[89]

Financial Performance - The company's operating revenue for 2019 was CNY 950,095,207.86, representing a 52.28% increase compared to CNY 623,904,151.91 in 2018[21] - The net profit attributable to shareholders for 2019 was CNY 301,147,028.57, a 65.99% increase from CNY 181,427,309.51 in 2018[21] - The net cash flow from operating activities reached CNY 215,374,300.86, up 127.22% from CNY 94,785,675.25 in the previous year[21] - Basic earnings per share for 2019 were CNY 1.10, a 66.67% increase compared to CNY 0.66 in 2018[21] - Total assets at the end of 2019 amounted to CNY 1,720,306,871.36, reflecting a 55.13% increase from CNY 1,108,964,590.51 at the end of 2018[21] - The company's net assets attributable to shareholders increased by 29.74% to CNY 1,145,941,429.17 from CNY 883,261,450.90 in 2018[21] - The company reported a weighted average return on equity of 29.68% for 2019, up from 21.43% in 2018[21] - The fourth quarter revenue was CNY 341,561,282.85, contributing significantly to the annual growth[23] - The company achieved a total operating revenue of 950.10 million yuan, an increase of 52.28% year-on-year[42] - Net profit attributable to shareholders increased by 65.99% compared to the previous year[42] Cash Flow and Investments - The net cash flow from operating activities was approximately ¥4.78 million, significantly lower than ¥141.35 million in the previous year[26] - The company reported a significant increase in inventory levels, with a 189.29% rise to 4,683.91 million units[84] - Operating cash inflow totaled ¥943.57 million in 2019, a year-on-year increase of 59.90%[95] - The net cash flow from financing activities surged to ¥233.67 million, a dramatic increase of 12,231.66% from the previous year[99] - The company has invested in fixed assets and construction projects, including new facilities in Hainan, Zhejiang, and Anhui, to support production capacity[47] - The total investment amount for the reporting period was ¥270,822,055.22, representing a 4.78% increase compared to ¥258,470,271.56 in the same period last year[109] Research and Development - The company has a robust pipeline of research and development projects, which are expected to drive future growth and innovation[48] - The company is increasing its investment in scientific research and development, aiming to innovate in areas such as allergy, oncology, cardiovascular, and pediatric medications[68] - The company’s R&D investment in 2019 amounted to approximately ¥204.37 million, representing 21.51% of its operating revenue[93] - The number of R&D personnel increased to 258 in 2019, accounting for 36.44% of the total workforce, up from 31.77% in 2018[93] Product and Market Strategy - The company operates an independent and complete procurement, production, and sales system[40] - The production model is based on "sales-driven production," aligning production plans with market demand[40] - The company has established a comprehensive GMP management system to ensure high production standards[40] - The sales strategy includes both distributor and delivery models, with a focus on academic promotion in hospitals[43] - The company has a diverse product portfolio covering multiple therapeutic areas, including anti-allergy drugs, non-steroidal anti-inflammatory drugs, antibiotics, and digestive drugs, with a focus on products like desloratadine and diclofenac[44] - The company is actively expanding its international market presence, having signed exclusive sales contracts with distributors in Europe and the United States[48] Risk Management and Future Outlook - The company highlighted potential risks in its future outlook, including industry policy changes and challenges in drug development[6] - The company anticipates potential risks from policy changes, international trade dynamics, and the complexities of drug development and quality assurance[137] - The company emphasizes the importance of internal governance and risk management as it scales its operations, aiming to enhance management levels and ensure timely information flow for decision-making[67] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 2.2 per 10 shares, with a capital reserve conversion of 5.5 shares for every 10 shares held[6] - The total distributable profit for 2019 is reported at 602,417,229.44 CNY, after accounting for a 10% legal surplus reserve deduction[146] - The company has consistently increased its cash dividends over the past three years, with 2018 and 2017 dividends being 2.1 CNY and 1.6 CNY per 10 shares, respectively[145][147] - The profit distribution plan for 2019 is subject to approval at the annual general meeting[146] Compliance and Governance - The board of directors has approved changes to accounting policies in response to new regulations issued by the Ministry of Finance, effective from April 30, 2019[196] - The company has committed to not transfer or entrust the management of its shares for 36 months following the IPO, ensuring stability in shareholding[159] - The company has established a strategy to avoid any conflicts of interest and reduce related-party transactions[173] - The company has ensured that there are no non-operational fund occupations by controlling shareholders or related parties during the reporting period[193]